U. Vehling‐Kaiser

发表

Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG).

M. Hallek, R. Busch, B. Eichhorst, 2007 .

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Hartmut Link, Michael Scholz, Thomas Kirchner, 2014, The Lancet. Oncology.

NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma—Very good response predominantly in patients with intestinal type tumors

V. Heinemann, A. Wein, K. Ridwelski, 2015, International journal of cancer.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

H. Einsele, W. Gesierich, A. Hinke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

W. Klapper, M. Hallek, S. Stilgenbauer, 2016, The Lancet. Oncology.

Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.

W. Scheithauer, M. Stauch, V. Heinemann, 2014 .

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

Michael Scholz, W. Scheithauer, M. Stauch, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

T. Gauler, T. Greten, V. Heinemann, 2014, BMC Cancer.

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104

U. Mansmann, T. Gauler, T. Greten, 2012, British Journal of Cancer.

Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

W. Scheithauer, V. Heinemann, T. Decker, 2014 .

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

W. Scheithauer, M. Stauch, V. Heinemann, 2016, The Lancet. Oncology.

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.

W. Scheithauer, M. Stauch, V. Heinemann, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial)

M. Stauch, A. Crispin, V. Heinemann, 2016, International journal of cancer.

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

Y. Ko, T. Gauler, T. Greten, 2012, Gut.

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

V. Heinemann, M. Welslau, J. Riera-Knorrenschild, 2022, ESMO open.

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

T. Decker, P. Klare, A. Hahn, 2020, BMC Cancer.

Lusorian artery lesion as rare cause of severe upper gastrointestinal tract bleeding

K. Jauch, E. Kaiser, G. Kueffer, 2005, Digestive Diseases and Sciences.

Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

M. Stauch, J. Trojan, R. Hofheinz, 2020, International journal of cancer.

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

A. Rosenwald, W. Klapper, E. Hoster, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer

F. Lordick, C. Peschel, J. Duyster, 2005, British Journal of Cancer.

Treatment of older patients with mantle-cell lymphoma.

W. Klapper, E. Hoster, B. Coiffier, 2012, The New England journal of medicine.

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’

T. Gauler, T. Greten, V. Heinemann, 2010, Anti-cancer drugs.

The CLL12 trial: Ibrutinib versus placebo in treatment-naïve, early stage chronic lymphocytic leukemia.

M. Stauch, M. Hallek, S. Stilgenbauer, 2021, Blood.

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

W. Klapper, H. Döhner, J. Franklin, 2020, HemaSphere.

Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II study in elderly patients or patients with impaired performance status.

F. Lordick, T. Schuster, C. Peschel, 2008, Critical reviews in oncology/hematology.

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)

M. Hallek, S. Stilgenbauer, K. Kreuzer, 2020, Haematologica.

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients

M. Hallek, S. Stilgenbauer, T. Decker, 2022, Leukemia & lymphoma.

Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study

M. Hallek, S. Stilgenbauer, K. Kreuzer, 2015 .

Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

M. Hallek, S. Stilgenbauer, K. Kreuzer, 2020 .

Bendamustine, Followed by Ofatumumab and Ibrutinib in Chronic Lymphocytic Leukaemia (CLL2-BIO): Primary Endpoint Analysis of a Multicentre, Open-Label Phase-II Trial

M. Hallek, S. Stilgenbauer, K. Kreuzer, 2019, SSRN Electronic Journal.

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

H. Döhner, U. Jäger, M. Hallek, 2017, Leukemia.

Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group

M. Hallek, B. Schmidt, S. Kremers, 2016, Leukemia & lymphoma.

University of Southern Denmark Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) Kutsch,

W. Klapper, H. Döhner, J. Franklin, 2020 .

Palliative home care for patients with advanced haematological malignancies—a multicenter survey

F. Nauck, B. Alt-Epping, W. Hollburg, 2017, Annals of Hematology.

Nutrition care in patients with cancer: A retrospective multicenter analysis of current practice - Indications for further studies?

M. Drissi, R. Radziwill, U. Vehling-Kaiser, 2015, Clinical nutrition.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Prevention and Treatment of Chemotherapy-Induced Neutropenia with the Biosimilar Filgrastim: A Non-Interventional Observational Study of Clinical Practice Patterns

H. Tesch, T. Ulshöfer, M. Turner, 2015, Oncology Research and Treatment.

A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions

M. Kindler, T. Steinmetz, U. Vehling-Kaiser, 2014, Current medical research and opinion.

Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine

V. Heinemann, U. Jehn, R. Bartl, 1999, Annals of Hematology.

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

W. Scheithauer, M. Stauch, V. Heinemann, 2017, International journal of cancer.

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

W. Scheithauer, M. Stauch, V. Heinemann, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study

V. Müller, S. Fuxius, C. Lerchenmüller, 2014, Oncology Research and Treatment.

Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

H. Döhner, U. Jäger, M. Hallek, 2020, Leukemia.

Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)

H. Döhner, U. Jäger, M. Hallek, 2013 .

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

V. Gebski, P. Gibbs, F. Lammert, 2017, The Lancet. Oncology.

Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

W. Klapper, E. Hoster, W. Hiddemann, 2017 .

LBA11INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE, EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306) IN THE FINAL RAS EVALUABLE POPULATION

W. Scheithauer, V. Heinemann, T. Decker, 2014 .

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

M. Stauch, V. Heinemann, H. Hass, 2014, Journal of Cancer Research and Clinical Oncology.

A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.

H. Kölbl, V. Heinemann, C. Ziske, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

V. Heinemann, T. Decker, G. Schuch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

M. Stauch, V. Heinemann, H. Hass, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer

M. Stauch, A. Crispin, V. Heinemann, 2017, Anti-cancer drugs.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

W. Scheithauer, M. Stauch, V. Heinemann, 2017, European journal of cancer.

Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)

V. Heinemann, S. Stintzing, A. Schalhorn, 2014, Anti-cancer drugs.

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)

W. Scheithauer, V. Heinemann, J. Holch, 2017, Oncotarget.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.

W. Scheithauer, V. Heinemann, T. Decker, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Relevance of liver‐limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE‐3/AIO KRK0306 trial

W. Scheithauer, V. Heinemann, J. Holch, 2018, International journal of cancer.

Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

P. Fasching, M. Stauch, V. Heinemann, 2008, Oncology.

Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

V. Gebski, P. Gibbs, F. Lammert, 2018, Clinical colorectal cancer.

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial

R. Porcher, H. Döhner, S. Leprêtre, 2013 .

High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer

M. Stauch, V. Heinemann, C. Jackisch, 2005, Oncology.

Inpatient Hospices in Germany: Medical Care Situation and Use of Supportive Oncological Therapies for Symptom Control in Tumor Patients

Ulrich Kaiser, Ana Hoffmann, F. Kaiser, 2022, Palliative medicine reports.

Use of symptom-focused oncological cancer therapies in hospices: a retrospective analysis

U. Vehling-Kaiser, N. Mechie, Ulrich Kaiser, 2020, BMC Palliative Care.

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

M. Bangerter, A. Hinke, V. Heinemann, 2011, BMC Cancer.

R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma

W. Klapper, E. Hoster, B. Coiffier, 2011 .

Consequences of the Corona crisis on outpatient oncological care – a qualitative study among nurses and medical assistants

U. Vehling-Kaiser, Ulrich Kaiser, Ana Hoffmann, 2022, PloS one.

The tumor patient in the COVID-19 pandemic–an interview-based study of 30 patients undergoing systemic antiproliferative therapy

Ulrich Kaiser, Ana Hoffmann, F. Kaiser, 2021, PloS one.

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL

M. Stauch, M. Hallek, S. Stilgenbauer, 2019, Hematological Oncology.

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

M. Stauch, V. Heinemann, H. Hass, 2011, British Journal of Cancer.

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

Michael Scholz, Volker Heinemann, W. Scheithauer, 2013 .

Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104

T. Gauler, T. Greten, V. Heinemann, 2015, Acta oncologica.

Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).

W. Scheithauer, V. Heinemann, T. Decker, 2018 .

Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

W. Scheithauer, M. Stauch, V. Heinemann, 2015 .

Oral and Subcutaneous Anticancer Therapy Training Course for Non-physician Healthcare Professionals: a Survey Evaluating the Relevance of its Content and its Implications in the Practice of Cancer Care

E. Shumilov, Ulrike Bacher, X. Schulz, 2020, Journal of Cancer Education.

Feasibility of Nurse Consultation in Oral Tumor Therapy: A Web-Based Survey among Physicians and Nonmedical Specialists

U. Vehling-Kaiser, W. Baumann, K. Hermes-Moll, 2019, Oncology Research and Treatment.

Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.

W. Scheithauer, V. Heinemann, T. Decker, 2018 .

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.

W. Scheithauer, P. Wirapati, H. Lenz, 2017 .

Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real‐world data from the noninterventional TACTIC study in Germany

T. Decker, F. Hartmann, M. Welslau, 2023, International journal of cancer.

Evaluation of gemcitabine plus carboplatin in pretreated, metastatic breast cancer patients: Final analysis of a phase II trial

P. Fasching, M. Stauch, V. Heinemann, 2007 .

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

W. Scheithauer, V. Heinemann, J. Holch, 2017, European journal of cancer.

Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study.

V. Heinemann, T. Decker, G. Schuch, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial.

M. Stauch, V. Heinemann, H. Hass, 2012 .

T. Decker, P. Klare, A. Hahn, 2020, BMC Cancer.

Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

A. Scharl, H. Meerpohl, F. Melchert, 2008, Oncology.

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer

M. Menden, J. Holch, Alexander J Ohnmacht, 2023, Nature communications.

Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group

M. Stauch, V. Heinemann, H. Hass, 2008 .

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

V. Heinemann, T. Decker, G. Schuch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

A. Kiani, S. Al-Batran, T. Kirchner, 2017, European journal of cancer.

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

W. Scheithauer, V. Heinemann, J. Holch, 2019, European journal of cancer.

Y. Ko, T. Gauler, T. Greten, 2012, Gut.

Nutrition care in patients with cancer: A retrospective multicenter analysis of current practice - Indications for further studies?

M. Drissi, R. Radziwill, K. Hengst, 2015, Clinical nutrition.

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.

E. Hoster, P. Feugier, H. Tilly, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306).

W. Scheithauer, M. Stauch, V. Heinemann, 2017 .

Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).

M. Stauch, V. Heinemann, D. Oruzio, 2010 .